



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 020716/S-012, S-013, S-014, S-015, S-016

SUPPLEMENT APPROVAL

AbbVie Inc.
One N. Waukegan Road
Dept PA77/Bldg. AP30
North Chicago, IL 60064

Attention: Patti Neall
Associate Director, Regulatory Affairs

Dear Ms. Neall:

Please refer to your following Supplemental New Drug Applications (sNDAs) and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for VICOPROFEN (hydrocodone bitartrate and ibuprofen) Tablets.

Supplement Number	Submission Date	Receipt Date
S-012	September 8, 2014	September 8, 2014
S-013	August 7, 2015	August 7, 2015
S-014	October 23, 2015	October 23, 2015
S-015	April 21, 2016	April 21, 2016
S-016	May 20, 2016	May 20, 2016

We also refer to our letter dated July 9, 2015, notifying you, under Section 505(o)(4) of the FDCA, of new safety information that we believe should be included in the labeling for the class of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). This new safety information pertains to the risks of Cardiovascular Thrombotic Events and Heart Failure and Edema.

Additionally, we refer to our letter dated March 22, 2016, notifying you, under Section 505(o)(4) of the FDCA, of new safety information that we believe should be included in the labeling for VICOPROFEN Tablets. This information pertains to the risks of misuse, abuse, addiction, overdose, death, and neonatal opioid withdrawal syndrome; serotonin syndrome with concomitant use of serotonergic drugs; adrenal insufficiency; and androgen deficiency.

Finally, we refer to our letter dated August 31, 2016, notifying you, under Section 505(o)(4) of the FDCA, of new safety information that we believe should be included in the labeling for VICOPROFEN Tablets. This information pertains to the risks of concomitant use of opioid analgesics with benzodiazepines or other central nervous system depressants.

Supplement S-012 provides for changes to the VICOPROFEN Tablets labeling to reflect the rescheduling of hydrocodone-containing products from schedule III into schedule II of the

Controlled Substances Act, in accordance with the final rule published in Federal Register on August 22, 2014, by the Drug Enforcement Administration.

Supplement S-013 provides for the Safety Labeling Changes required under Section 505(o)(4) of the FDCA, for the class of NSAIDs, consistent with our July 9, 2015, letter.

Supplement S-014 proposes additional revisions to the Package Insert to incorporate NSAID analgesic product class template language, consistent with our July 9, 2015, letter.

Supplement S-015 provides for the Safety Labeling Changes required under Section 505(o)(4) of the FDCA, consistent with our March 22 and August 31, 2016, letters.

Supplement S-016 proposes additional revisions to the Package Insert to incorporate the opioid analgesic class template language, consistent with our March 22, 2016, letter.

APPROVAL & LABELING

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling text, with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

Marketing the product(s) with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

OPDP Regulatory Project Manager
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)
5901-B Ammendale Road
Beltsville, MD 20705-1266

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at:

<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf>).

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at

<http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>.

Information and Instructions for completing the form can be found at

<http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above, by fax to 301-847-8444, or electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at:

<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf>).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Mark Liberatore, PharmD; Safety Regulatory Project Manager, at (301) 796-2221.

Sincerely,

{See appended electronic signature page}

Sharon Hertz, MD
Director
Division of Anesthesia, Analgesia,
and Addiction Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

SHARON H HERTZ
12/16/2016